Gastrointestinal Cancers News
Elevated levels of inflammatory biomarkers are associated with worse outcomes for patients with stage III colon cancer, a study suggests.
Larotrectinib prolongs survival when compared with non-TRK inhibitor standard care in adults with TRK fusion-positive cancers, a study suggests.
Six weeks of neoadjuvant chemotherapy was associated with a higher rate of complete resection and a lower rate of disease recurrence.
The use of bariatric surgery in patients with severe obesity is associated with a reduced incidence of esophageal and gastric cancers.
Centers that perform comprehensive cancer screening in a single appointment may enable earlier cancer diagnosis.
Postmenopausal cancer survivors have greater declines in physical function than cancer-free control individuals, a new study suggests.
Cancer patients have an increased risk of suicide when compared with the general population in the United States, a study suggests.
A decision support system called GI TARGET may help integrate precision medicine into routine care for patients with gastrointestinal cancer, according to researchers.
Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.
A nonsurgical treatment strategy employing chemoradiotherapy is feasible for patients with early rectal cancer, a phase 3 trial suggests.
Follow-up colonoscopy rates were 43.3% within 90 days of a positive stool-based screening test and 56.1% within 360 days.
Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.
The prevalence of advanced colorectal neoplasms was 40% to 50% lower among patients who underwent repeated screening at least 10 years after a negative colonoscopy.
Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
The approval was based on data from the phase 2 MOUNTAINEER trial, which included patients with HER2-positive. unresectable or metastatic colorectal cancer.
Monitoring of ctDNA may be useful for early response assessment in patients with anal cancer receiving chemoradiation, a study suggests.
Combination botensilimab and balstilimab elicits durable responses in refractory, metastatic, microsatellite-stable colorectal cancer, a phase 1 trial suggests.
NALIRIFOX outperformed treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer in the NAPOLI-3 trial.
Nanvuranlat improved progression-free survival, compared with placebo, in heavily pretreated patients with advanced biliary tract cancer.